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Transmission of cytomegalovirus infection with renal allograft.
Fifty-four patients who received a renal allograft between October
1971 and October 1974 were followed prospectively to correlate
pretransplant serum antibody to cytomegalovirus (CMV) with
shedding of CMV following transplantation. Twenty-five of 54
patients had antibody demonstrable to CMV using immunofluores-
cent techniques, but only 20 of 54 using complement-fixing tech-
niques. All 24 who had antibody and survived one month or
longer, and seven of nine without antibody but who received a
kidney from a seropositive donor shed virus after transplantation,
whereas none of 12 individuals without antibody and who received
a kidney from a seronegative donor (P < 0.005) shed virus. Three
of eight other seronegative patients for whom donor sera were not
available for analysis shed virus. Viremia occurred in eight of ten
individuals who developed new antibody after transplantation,
versus seven of 24 with antibody prior to transplant (P < 0.02),
and virus shedding in seroconverters from other sites was signifi-
cantly more persistent than in pretransplant antibody-positive
patients. Thus, CMV infection was due either to reactivation of
latent infection or was transmitted along with the renal allograft
and manifested as a primary infection.
Transmission de l'infection a cytomegalovirus par Ia greffe rénale.
Cinquante quatre malades qui ont recu une greffe rénale entre
octobre 1971 et octobre 1974 ont été suivis de facon prospective
afin de corréler les litres d'anticorps sériques anticytomegalovirus
(CMV) avec l'excrétion de CMV aprés Ia transplantation. Vingt-
quatre des cinquante-quatre malades avaient des anticorps anti
CMV mis en evidence par les techniques d'immuno-fluorescence,
mais vingt seulement sur cinquante-quatre au moyen des tech-
niques de fixation du complement. Tous les 24 malades qui avaient
l'anticorps et qul ont survécu un mois ou plus et 7 parmi 9 malades
qui n'avaient pas l'anticorps mais qui avaient recu un rein de
donneur séropositif ont eu une excretion virale alors qu'aucun des
12 sujets sans anticorps et qui avaient reçu des reins de donneurs
séro-négatifs n'ont eu d'excrétion virale (P < 0,005). Trois parmi 8
malades sero-negatifs dont le serum des donneurs n'avait pas été
étudié ont eu une excretion virale. La virCmie est survenue chez 8
parmi lJ sujets qui ont développé de nouveaux anticorps aprés Ia
transplantation contre 7 parmi 24 malades qui avaient lanticorps
avant Ia transplantation (P < 0,02), et l'excrétion virale a été
significativement plus persistante chez les premiers que chez les
derniers. Ainsi I'infection a CMV est due ou a a reactivation d'une
infection latente ou a Ia transmission par Ia greffe rénale et se
manifeste alors comme une infection primaire.
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Cytomegalovirus (CMV) infection is frequent fol-
lowing renal transplantation. This was first docu-
mented morphologically in 1964 [1, 2], and sub-
sequently by recovery of virus from infected patients
[3, 4]. Numerous reports have confirmed these find-
ings, and have noted the incidence of infection to be
between 40 and 90% of transplanted patients [5-20].
Various studies have suggested that CMV might
account for the majority of cases of hepatitis [II, 14-
16, 19-21], unexplained fever with or without pneu-
monia [6, 8, 10-12, 14, 15, 17-21] and possibly even
rejection [17, 18, 20] following transplantation, and
that these problems may be more common in patients
developing apparent new infection than in those with
reinfection. Much of the information is, however,
retrospective in nature.
Cytomegalovirus infection has been found to be
more frequent in individuals who possessed serum
antibodies to CMV prior to transplantation than in
those lacking such antibodies, but has also occurred
in individuals who were antibody-negative [4, 7-10,
12, 14, 16, 19-21]. To account for development of
infection in individuals without previous antibody,
person-to-person transmission ofvirus [3, 7,9, 13, 19,
20] and presence of virus in blood transfusions [7, 9,
10, 12, 14, 16, 21] have been suggested as possible
sources. Very little attention has been given to the
donor kidney as a possible source. Using the com-
plement-fixing (CF) antibody test Hedley-Whyte and
Craighead found the donor to their patient to be CF-
negative [3] as did Balakishnan et al [10] whereas
Armstrong et al found that one of two donors to
seronegative patients was CF-antibody positive [12].
In most reported studies where individuals have
undergone seroconversion after transplantation, the
CF antibody test was used. It has been shown by
Waner, Weller and Kevy that CF antibody to CMV
may be intermittently positive in individuals tested
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serially [22]. This suggests that if only a single serum
is analyzed, the CF antibody test may not be an ade-
quate test of latent infection. In 1970, the immu-
nofluorescent (FA) technique to measure IgG anti-
bodies was applied to CMV infection by Chiang,
Wentworth and Alexander [23] but it has received
only limited use [13, 24, 25]. Available data suggest
that the FA test has equal [24, 25] or greater [13, 23]
sensitivity than the CF test.
In order to delineate the predictive value of FA
status of the patient prior to transplantation on the
development of CMV infection after transplantation,
we studied prospectively 54 patients who underwent
renal allotransplantation between October, 1971 and
October, 1974 at the University of Rochester Medical
Center. We attempted to determine whether CMV
infection after transplantation could be accounted for
by reactivation of latent infection or acquisition of
new infection. In addition, sensitivity of the FA test
was compared to that of the CF and neutralizing
antibody tests.
Methods
Patients. The 54 patients had been maintained on
hemodialysis at one of the Rochester Regional Net-
work dialysis centers (the Strong Memorial, Roches-
ter General, Monroe Community and the Genesee
Hospital in Rochester and the Arnot-Ogden Hospital
in Elmira, New York). Their characteristics are de-
picted in Table I.
Immunosuppressive protocol. Azathioprine, 8 mg/
kg, was administered the day of transplantation, 6
mg/kg the next day, and subsequent doses were ad-
justed to maintain the white blood cell count between
5,000 and 10,000/mm3 with most patients receiving 1
to 2 mg/kg/day. Two milliliters of antilymphocyte
globulin (3.5 to 6 g/l00 ml of protein) was adminis-
tered daily for the first 14 days, then discontinued.
Sixty milligrams/day of prednisone in divided doses
was administered for at least two weeks, then gradu-
ally tapered to a minimum maintenance dose. All and
only cadaver recipients received routine radiation of
600 rads in four divided doses to the allograft and
surrounding areas. Acute rejection episodes were
Table 1. Characteristics of patients studied
Patients, N 54
Mean age,yr 31.2
Less than age 20 yr. N 9
Males, N 30
Cadaveric recipients, N 38
Length of time dialyzed (mean), months 15.2
treated with methylprednisolone delivered in a bolus
of 0.5 to 1.0 g daily for three days. An occasional
patient with rejection, resistant to bolus therapy, un-
derwent a repeat course of' radiation.
Tissue culture and media. Human embryonic lung
fibroblasts (WI-38) were obtained from Flow Labora-
tories, Bethesda, Maryland and maintained as de-
scribed previously [7] except that the temperature
throughout the study was 33°C. These cells were uti-
lized for all phases of the study including antigen
preparation.
Specimens. All specimens were collected during
working hours and transported on wet ice to the
laboratory and inoculated the same day. The follow-
ing samples were collected weekly for six weeks, then
biweekly for six weeks, and monthly for two months
following transplantation: 10 ml of heparinized
blood, 10 ml of clotted blood, 3 to 4 ml of anterior
oral secretions and 10 or more ml of urine when
available. Specimens were prepared and inoculated as
previously described [5, 7, 12].
Virus isolation. This was carried out as described
previously [3]. CMV was identified by typical cytopa-
thic effect with slow progression. Cells were observed
twice-weekly and were blind-passaged once at ap-
proximately five weeks after inoculation and ob-
served 30 additional days before being regarded as
negative.
Virusstocks. Ad 169 was obtained from Flow Labo-
ratories and ED was isolated and identified in our
laboratory using hyperimmune sera prepared in our
laboratory against Ad 169 as described by Huang,
Huang and Pagano [26].
Complement-fixing antibody test (CF). Antigenwas
prepared every three months as previously described
by Hanshaw [27], six days after infection [28] using
high titered virus inoculum [29] and was stored at
—70°C. Selection of antigen concentration and ap-
propriate controls were carried out as described pre-
viously [30] and each new antigen was retested with
our known positive sera before use. Results using ED
antigen were compared to AD 169 on 30 sera which
were positive to AD 169. Use of ED antigen resulted
in a higher titer in 12, an equal titer in 16 and a lower
titer in 2. Furthermore, ED antigen gave a positive
result in six sera which were negative using AD 169
antigen. Confirmation of the results of CF tests of 16
sera was carried out at the Communicable Disease
Center in Atlanta, Georgia. The antigen used was
AD 169 and the results were identical or differed by
one dilution from our results. In order for a serum to
be considered CF-negative, the result had to be nega-
tive with both antigens employed.
Immunofluorescentantibody test (FA). Fluorescein-
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conjugated anti-human IgGFc fragment was ob-
tained from Hyland Laboratories. The preparation of
antigen and mechanics of antibody testing were as
described by Chiang, Wentworth and Alexander [23].
Antigen samples on glass slides were stored at —70° C
and retained activity for up to four months although
the slides were used within 30 days of preparation.
Newly prepared antigen was tested with a known
positive serum. All sera were coded prior to being
tested and were considered positive if specific nuclear
fluorescence was demonstrable using a serum dilution
of one to four or greater.
Neutralizing antibody. This was essentially as de-
scribed by Rifkind, Goodman and Hill [6] except that
microtiter plates were used instead of tubes.
Results
Comparison of different antibody tests in pre-
transplant sera. A serum specimen was collected imme-
diately prior to transplantation from each of the 54
patients. In addition, four or more serum specimens
were obtained over the period of hemodialysis (6 to
36 months) from 49 patients and one to three sera
were obtained from the other 5 patients. The 54 pre-
transplant sera were tested for antibody to CMV us-
ing CF, FA and neutralization techniques (see Table
2). Twenty-five of the 54 patients were positive for
antibody by at least one of these three techniques.
The additional serum specimens obtained while these
patients were receiving hemodialysis were stored at
—20°C and were also tested. In 25 patients who were
antibody-positive immediately before transplanta-
tion, 94 of the 97 additional sera were positive by
at least one of the three methods (Table 2). Com-
parison of results of testing sera by three different
methods is shown also in Table 2. The FA test was
more frequently positive than either the CF or the
neutralization tests. The FA test detected antibody in
serum specimens obtained just prior to trans-
plantation in all 25 individuals shown to possess anti-
body by any test at any time prior to transplantation
and in all 18 patients whose serum specimen was
obtained prior to initiation of hemodialysis. Of the
122 sera available from other time points on hemo-
dialysis, 119 of these were positive by the FA tech-
nique. The CF test failed to detect antibody in a
substantial number of serum samples taken at differ-
ent times during hemodialysis and even when mul-
tiple sera obtained over the entire hemodialysis pe-
riod were tested, the total number of individuals with
CF antibody only increased to 20 (not shown).
The neutralizing antibody test has not been as ex-
tensively studied, but it was not positive in any
patient who did not have antibody detected by other
means, and was positive in only 21 of 25 patients with
FA antibodies. Of the 21 patients with neutralizing
antibody, 15 were positive by FA and CF, and 6 were
FA-positive and CF-negative.
Eighty-four other serum specimens were available
for testing in the 29 individuals whose immediate
pretransplant serum sample was FA-negative. The
FA antibody determination was consistently negative
in all of these other sera obtained from these individ-
uals while they were receiving dialysis. Thus, not only
was the FA test more sensitive than either the CF test
or the neutralizing antibody test but it more clearly
differentiated patients into those who were antibody-
positive and those who were antibody-negative.
Comparison of characteristics of patients grouped
according to pretranspiant and posttransplant anti-
body. Analysis of FA status prior to and after trans-
plantation revealed that our patients fell into three
distinct groups (Table 3). Patients in group I (sero-
positive) possessed antibody prior to transplantation
and retained antibody after transplantation. A four-
fold rise in titer occurred in 19 of 25 patients follow-
ing transplantation. Patients in group 11 (seroconver-
ters) did not have antibody in 61 serum samples
collected while they were receiving maintenance
hemodialysis, but they all developed antibody after
transplantation. Those in group III (seronegative)
Table 2. Comparison of frequency of detection of antibodies to cytomegalovirus measured by lgG
immunofluorescence (FA), complement fixing (CF) and neutralizing tests in patients prior to renal
transplantation
.
Antibody in serum
immediately before
transplantation
Sera positive by each test at indicated time, N
Immediately prior
to transplantation First dialysis Subsequent dialysis
Total Sera
patients tested, N CF FA Neut.
Sera
tested, N CF FA
Sera
tested, N CF FA
Yes 25 25 15 25 21 18 12 18 79 31 76
No 29 29 0 0 0 23 0 0 84 0 0
0 1 2 3 4 5
jilo,,ths after transplantation
Secretions
100
75
50
25.
Ui;
l00I:_
751
501
25'
0
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Table 3. Characteristics of patients in relation to presence of anti-CMV antibody prior to
transplantation and shedding of CMV after transplantation
Presence of anti-CMV
antibody prior to
transplantation
Group I
Absence of anti-CMV antibody
prior to transplantation
Group II Group 111
Patients,N 25 10 19
Males,N 15 5 10
Mean age, yr 34.2 25.8 29.8
Cadaver recipients, N 22 4 12
Timedialyzed(mean),months 15.4 10.4 18.4
Patients shedding CMV, N 24 10 0
Patients with FA antibody response
(fourfold),N 19 10 0
P < 0.02 group I vs. group II.
had no antibody prior to transplantation and did not
develop antibody after transplantation. Group I had
a higher ratio of males to females and the patients
were somewhat older as compared to group II and
group III but these differences were not significant.
More patients in group I received cadaver kidneys
than in group ll(x2 = 5.45, P < 0.02) or group iII(x2
= 2.51, P> 0.2). The mean length of time on dialysis
was somewhat shorter in group II than either group I
or group III. This was because there were more living
related donor kidney recipients in group II.
All but one individual with antibody prior to trans-
plantation (group I) shed virus after transplantation
and the single exception died three weeks after trans-
plantation. All ten group 11 patients (seroconverters)
shed virus after transplantation whereas none of the
group Ill patients (seronegative) shed virus (P <
0.001). Furthermore, the culture-negative status after
Fig. 1. Comparative frequency of positive cultures at different times
following transplantation in blood (o--o--o), anterior oral secretions
(o——o——o), and urine (o . . o . o) in group I (sero-
positive) and group II (seroconverters) patients (see lest for statis-
tical analysis). Bar graph shows comparative percentage of patients
who shed virus from the designated site at any time during the
follow-up period.
transplantation of group 111 patients was established
with 211 attempts to isolate virus.
Cytomegalovirus shedding patterns in group I and
group Ilpalienls. As shown in Table 3, there was no
clear correlation between source of kidney or length
of time on dialysis and frequency of virus shedding
after transplantation. To determine whether there
were any differences in shedding patterns between
group I and group II, the onset, incidence and per-
sistence of shedding of CMV after transplantation
were assessed and the results are shown in Fig. 1.
Specimens from the two groups were collected with
the same frequency. The average number of speci-
mens tested per patient of blood, anterior oral secre-
tions and urine was similar in group I as compared to
11(9.1 vs. 11.9), (8.9 vs. 9.1) and (5.2 vs. 7.8). As
shown in Fig. 1, a small percentage of specimens
from group I patients was positive slightly earlier
after transplantation than those from group 11
patients. However, mean time of onset of shedding
was nearly identical (44.1 vs. 43.1 days).
Viremia in group II patients was significantly more
frequent than in group I but the incidence of shed-
ding in the other two tested sites (urine and oral
secretions) was not different. However, comparing
the specimens collected between one month after
transplantation (onset of first virus shedding in any
patient) and five months after transplantation
showed that isolation of virus from all three sites was
significantly higher in group 11 compared to group I
(blood, 24/57 vs. 12/134; AOS, 51/60 vs. 70/127;
urine, 43/52 vs. 49/107, a difference which was highly
significant for all three sites, P < 0.001).
Frequency of blood transfusions to the different
groups. Group I patients were antibody-positive be-
fore transplantation and shed virus after trans-
plantation implying reactivation of latent infection
whereas group II patients were antibody-negative be-
fore transplantation but developed antibody after
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Table 4. Relationship of the number of transfusions administered during hemodialysis to pre-
and posttransplant serologic status of transplant patients
Period
evaluated
Serologic status of recipients
Group I
(seropositive)
Group II
(seroconverters)
Group III
(seronegative)
Hemodialysis period
Transfusions per month per
patient (mean), N
Total transfusions per patient
(mean), N
Peritran splant perioda
Transfusions per patient (mean),
N
2.4
36.3
6.7
2.5
24.6
5.5
1.6
29.0
5.7
Four weeks before to two weeks after transplantation.
transplantation and shed virus implying new in-
fection. Transfused blood was one possible source for
transmission of primary CMV infection. Since virus
shedding occurred at the same time after trans-
plantation in group II as in group I patients, the
blood administered around the time of trans-
plantation would be suspect as a carrier. It is also
possible that earlier transfusions might have con-
tained virus that remained latent in the recipient until
after transplantation. Accordingly, we compared
transfusions given either while the patient was receiv-
ing dialysis or around the time of transplantation (see
Table 4). All transfusions were administered as
washed, frozen, then thawed red blood cells.
Analysis of the number of transfusions adminis-
tered over the entire hemodialysis period revealed
that group I patients received a greater number of
transfusions per patient totally than either group II
or group III patients, but group II patients received
slightly more per month of hemodialysis than group I
or III patients. We attempted to isolate CMV from
the first 85 U administered during the early part of
our study. These attempts were made from the cells
after they had been washed, frozen and thawed. No
virus was isolated from any of the units. Separate
analysis of the transfusions administered in the per-
itransplant period revealed that the number of trans-
fusions administered per patient to each group was
not different. Thus, the frequency of transfusion to
group II and group III patients was the same.
Relationship between serologic status of the donor
and CMV infection in the recipient. As mentioned pre-
viously and demonstrated in Fig. 1, onset of shedding
after transplantation occurred at almost the same
time in group I and group II patients. Therefore,
acquisition of virus by group II patients must have
occurred either prior to or at the time of trans-
plantation. One other possible source of new CMV
infection to consider was the transplanted kidney.
Serum samples from 29 donors were evaluated us-
ing all three antibody techniques. Of the 29, eight
donated a kidney to group I patients, seven to group
II patients and 14 to group III patients. In group I,
three kidneys were from seropositive donors and five
from seronegative donors. As shown in Table 5, nine
kidneys of seropositive donors were transplanted to
seronegative recipients (group II and III), and seven
of these recipients shed CMV and developed anti-
body to CMV after transplantation. Twelve kidneys
from seronegative donors were transplanted to sero-
negative recipients and none of these recipients either
shed CMV or developed anti-CMV antibody (x2 =
10.71, P < 0.005).
Discussion
We have prospectively studied 54 patients, main-
tained on repetitive hemodialysis, all of whom sub-
sequently underwent renal transplantation. Studies
included serial CMV antibody determinations prior
Table 5. Relationship of antibody status of donor to development of subsequent CMV
infection among antibody-negative recipientso
Antibody status
Kidneys tran
to each patien
splanted
t group, N
Group II Group III
of donor (seroconverters) (seronegative)
Positive 7 2
Negative 0 12
x2 Yates correction = 10.71, P < 0.005.
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to transplantation correlated with shedding patterns
of CMV from blood, oral secretions and urine after
transplantation. We evaluated the relative sensitivity
of neutralizing, CF and FA tests.
Previous authors have noted that neutralizing [6, 8,
19, 31] and immunofluorescent [13] antibodies to
CMV are more frequently detected than CF anti-
bodies in transplant recipients. Of the 34 patients in
our study who shed CMV after transplantation, 24
had FA activity, 21 neutralizing antibody and only 1 5
CF antibody. When a number of sera were tested on
these patients, the number with positive CF antibody
increased to 20 while virtually all sera from antibody-
positive patients contained FA activity prior to trans-
plantation.
However, there were ten patients who shed virus
after transplantation in whom we were unable to de-
tect pretransplant CMV antibody despite testing a
total of 61 stored serum specimens from these
patients. All ten of these patients, however, did de-
velop antibody after transplantation. It is likely,
therefore, that these ten individuals (group II) devel-
oped a primary infection after transplantation. Fur-
thermore, the increased frequency of viremia and
more persistent shedding from all sites in group II
patients compared to group I patients (seropositive)
is consistent with primary infection. In contrast, the
presence of antibody before transplantation and virus
shedding data after transplantation in group I
patients suggests reactivation of latent infection.
We attempted to differentiate whether the source
of new virus infection in group 11 patients was blood
transfusions as has been suggested in postperfusion
syndrome [32] or the kidney itself. Our data suggest
that blood transfusions were not the source. First,
antibody did not develop in group II patients during
a mean of 10.4 months on dialysis during which time
they received an average of 2.4 transfusions per-
month. Second, the frequency of transfusions to
group 11 and Ill patients both over the entire dialysis
period or around the time of transplantation was
nearly identical. Third, we were unable to isolate
CMV on 85 attempts from the washed frozen, then
thawed red blood cells. Although in the post-
perfusion syndrome blood transfusion has been impli-
cated as a source of CMV, it is felt that large numbers
of fresh blood transfusions increase the chance of
transmission of CMV infection. However, in our
transplant program fresh blood is specifically avoided
in the hemodialysis patient who is a potential trans-
plant recipient, which may explain why transfusion
does not appear to be a source of virus infection in
our study.
Our data, instead, suggest strongly that new virus
infection was transmitted along with the transplanted
kidney. This contention is supported by the high fre-
quency of seroconversion in seronegative individuals
who received a kidney from a seropositive donor, and
the lack of development of infection in seronegative
individuals who received a kidney from a seronega-
tive donor and the nearly identical mean time of on-
set of infection in group I and II patients after trans-
plantation. Thus, using the FA test we were able to
account for virus shedding after transplantation in 31
of 34 individuals, 24 were accounted for by reac-
tivation of latent infection and, in addition, 7 by
transmission along with the donor kidney. The other
three virus shedders could not be accounted for but
donor sera to these three patients was not available
for analysis. The FA test appears to be as useful in
CMV infection as it has in Epstein-Barr virus in-
fection [33], both as a screening test of previous in-
fection and also for detection of new infection.
However, our data do not allow differentiation of
the specific cell that contains the transplanted virus.
It could either be carried in renal parenchymal cells
or in circulating white blood cells from the donor that
might have been trapped in the kidney when it was
removed for transplantation. Although normal hosts
who are infected with CMV shed virus in their urine
and both congenitally infected infants [34] and
patients with disseminated CMV infection [5, 35]
have intranuclear inclusions in their kidneys, there is
no information as to whether the seropositive normal
host carries latent CMV in the kidney parenchymal
cells. On the other hand, apparently asymptomatic
normal individuals may have CMV in their circulat-
ing white blood cells [36], and if these cells were
trapped in the renal allograft at the time it was re-
moved for transplantation, these cells could be the
source of virus infection. Whichever cell is the source
of virus, the process of transplantation of a non-HLA
identical renal allograft or the administration of the
immunosuppressive drug regimen separately or to-
gether lead to reactivation of latent CMV infection
and in some patients dissemination of that infection
[5].
Previous reports have suggested that clinical illness
is more common in those who seroconvert from nega-
tive to positive [4, 8-10, 12, 14, 16, 19-21] compared
to those who were pretransplant antibody-positive
although in those reports some individuals with pre-
transplant antibody did develop illness after trans-
plantation, apparently due to CMV. This suggests
that most clinical illness may be a consequence of
transplantation of virus to a previously unexposed
individual. Furthermore, Lopez et al [17] and Sim-
mons et al [18], as well as other investigators [11, 20,
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37], have provided interesting information that CMV
infection is associated with renal rejection. If CMV
were latent in renal parenchymal cells (see above),
replication of virus could result in new antigens in or
on renal parenchymal cells, which could add to the
degree of mismatch of the kidney and possibly con-
tribute to rejection.
In order to better evaluate the role of CMV in
acute illnesses after transplantation and also whether
or not CMV might be contributing to the rejection
process, future studies need to take into account the
serologic status of both the donor and recipient. Fur-
thermore, since CMV infection is also a frequent
problem associated with donation of other organs
[38], this study suggests that donors and recipients of
transplanted organs will need to be studied using the
FA antibody test for CMV to distinguish between
acquisition of new infection versus reactivation of
latent infection. Such studies will be necessary to de-
cide whether potential donors to seronegative
patients will need to be screened using the FA tech-
nique as part of the pretransplantation screening
process to determine organ suitability.
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